Cogent Biosciences Q3 2026 Results: Net Loss of $111M, Loss Widens
Cogent Biosciences reported a net loss of $305.2 million for the nine months ended September 30, 2026, compared to $226.4 million in the prior year period, driven by increased R&D and G&A expenses. The company maintained a strong liquidity position with $791.1 million in cash, cash equivalents, and short-term marketable securities as of September 30, 2026.
- Key figure
- Net loss $111M